Short Interest in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Expands By 37.5%

LeMaitre Vascular, Inc. (NASDAQ:LMAT) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 1,210,000 shares, an increase of 37.5% from the December 31st total of 880,000 shares. Approximately 5.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 157,900 shares, the days-to-cover ratio is presently 7.7 days.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LMAT. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective for the company. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Barrington Research upped their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $94.57.

Insider Activity

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.79% of the stock is currently owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

A number of institutional investors have recently modified their holdings of LMAT. NBC Securities Inc. boosted its holdings in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the last quarter. USA Financial Formulas acquired a new position in shares of LeMaitre Vascular during the 3rd quarter worth about $60,000. GAMMA Investing LLC grew its holdings in shares of LeMaitre Vascular by 34.3% in the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 188 shares in the last quarter. KBC Group NV grew its holdings in shares of LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 410 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of LeMaitre Vascular in the fourth quarter valued at about $150,000. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $96.93 on Friday. The firm has a market cap of $2.18 billion, a P/E ratio of 52.97, a PEG ratio of 2.20 and a beta of 0.96. LeMaitre Vascular has a twelve month low of $56.61 and a twelve month high of $109.58. The firm’s 50 day moving average price is $97.41 and its two-hundred day moving average price is $92.85.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm’s revenue was up 15.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.33 EPS. On average, sell-side analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.